BioAge Labs (BIOA) Receivables - Net (2025 - 2026)
BioAge Labs' (BIOA) quarterly Receivables - Net came in at $625000.0 in Q2 2026, up 3.65% year-over-year from $603000.0 in Q2 2025, and down 11.85% quarter-over-quarter from $709000.0 in Q1 2026.
Powered by 
Analysis
BioAge Labs (BIOA) Receivables - Net (2025 - 2026) Analysis & Trends
BioAge Labs has disclosed Receivables - Net across 2 years of filings, most recently posting $625000.0 for Q2 2026.
- In Q2 2026, Receivables - Net rose 3.65% year-over-year to $625000.0; the TTM figure through Jun 2026 stood at $625000.0 (up 3.65% YoY), while the FY2025 annual figure was $769000.0, changed N/A from the prior year.
- Receivables - Net came in at $625000.0 for Q2 2026 at BioAge Labs, down from $709000.0 in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $769000.0 in Q4 2025 to a low of $361000.0 in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn |
| 10 | BioAge Labs | 409.83 Mn | 409.83 Mn | -14.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 625,000.00 |
| Mar 31, 2026 | 709,000.00 |
| Dec 31, 2025 | 769,000.00 |
| Sep 30, 2025 | 515,000.00 |
| Jun 30, 2025 | 603,000.00 |
| Mar 31, 2025 | 361,000.00 |